The research, published in the prestigious journal Lab Animal, details how the Exeter team adapted cutting-edge genetic technologies, including PiggyBac transgenesis and CRISPR/Cas9 gene editing, originally developed in fruit fly studies, to generate fluorescent transgenic and gene knockout lines of the greater wax moth. This feat surmounts a significant barrier that has historically limited the utility of Galleria mellonella, a model organism increasingly recognized for its cost-effectiveness and ethical advantages. Unlike many alternative models, these moths can be raised at 37°C, the exact human body temperature, facilitating a more physiologically relevant environment for infection research.

What makes Galleria mellonella remarkably valuable is its immune response, which closely parallels mammalian innate immunity in battling bacterial and fungal infections. Until now, however, the moth’s lack of genetic tractability hindered in-depth mechanistic studies and the development of real-time, dynamic infection biosensors. By harnessing transgenic technology, the Exeter researchers have now enabled the generation of “sensor moths” that emit fluorescence in response to infection or antibiotic exposure. This innovation provides researchers with an unprecedented living window into host-pathogen interactions, offering continuous, non-invasive monitoring of infection progression and treatment efficacy.

Dr. James Pearce, a leading scientist on the project, emphasized the urgent necessity for new research modalities in the face of mounting AMR challenges. “Engineered wax moths present a fast, ethical, and scalable approach to infection research,” Pearce explained. “Our work eliminates a critical bottleneck, positioning these insects to replace mammalian models in many scenarios while delivering data that is highly predictive of human outcomes.” This resonates strongly with the ethical imperative to reduce animal suffering and the practical imperative to accelerate drug discovery pipelines.

A unique feature of Galleria mellonella is its ability to host human pathogens such as Staphylococcus aureus—a notorious superbug—and Candida albicans, a common opportunistic fungal pathogen. The larvae’s responses to these infections mirror those seen in mammals, making them an ideal intermediate model bridging simplistic cell cultures and complex mammalian experiments. By genetically modifying these moths, researchers can now interrogate immune pathways with unparalleled precision and validate antimicrobial candidates in a living organism that more accurately represents human infection dynamics.

Professor James Wakefield highlighted the advantages of visualizing the infection process in real time: “Genetically engineered fluorescence enables us to build biosensor systems within the moth, giving immediate feedback when infection sets in or when antimicrobial agents act.” This form of live imaging bypasses many limitations of endpoint assays and invasive sampling in rodents, enabling more refined and ethical experimentation. It also opens avenues for high-throughput screening of novel compounds, potentially shortening the timeline from discovery to clinical application.

The implications for animal welfare and the 3Rs principle—replacement, reduction, and refinement of animal use in scientific research—are profound. Current estimates indicate that approximately 100,000 mice are used annually in the UK for infection biology studies alone. If the wax moth model replaces just a fraction of these experiments, thousands of rodents could be spared each year without compromising scientific rigor. Moreover, scaling insect colonies is considerably more cost-effective and resource-efficient compared to maintaining mammalian facilities, presenting further logistical benefits.

The development at Exeter underscores a broader trend towards refining research models with advanced genetic toolkits. The integration of PiggyBac-mediated transgenesis—a technique that allows stable gene insertion—and CRISPR/Cas9-mediated gene knockout provides remarkable flexibility in manipulating the moth’s genome. This dual approach allows researchers to both illuminate cellular responses via fluorescent markers and dissect gene function by targeted deletion, facilitating a comprehensive understanding of host-pathogen interactions and gene roles in immunity.

Furthermore, the Exeter team has institutionalized their innovation by establishing the Galleria Mellonella Research Centre, a collaborative hub supporting over twenty research groups worldwide. This center not only supplies genetically modified moth lines but also offers training and standardization resources, fostering global adoption of this model and enhancing reproducibility across laboratories. Such openness and collaboration accelerate the pace of discovery and ensure that these technological advances benefit the wider scientific community rapidly.

This study also reflects a successful partnership between academia and government bodies, including investment from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) and collaboration with the Defence Science and Technology Laboratory. These alliances highlight the recognition of alternative research models as vital tools in public health strategy and biosecurity preparedness, particularly in combating resistant infections.

Looking ahead, the capacity to engineer live biosensors within Galleria mellonella larvae heralds a future where infection research is not only more humane but also more insightful. By enabling dynamic, real-time reporting of infection and immune responses within a whole organism, this platform provides a powerful new lens through which scientists can visualize the complexities of microbial pathogenesis and host defense. Such insights are essential for developing next-generation antimicrobials that can outpace evolving resistance.

In summary, this breakthrough ushers in a new era whereby an insect model, genetically engineered for the first time, stands to reshape infectious disease research. With profound ethical, scientific, and economic advantages, this innovation offers a compelling solution to accelerate antimicrobial research without compromising on human relevance or animal welfare. The future of infection biology may well glow—in vibrant fluorescence—within the humble wax moth.

Subject of Research: Animals

Article Title: PiggyBac mediated transgenesis and CRISPR/Cas9 knockout in the greater waxmoth, Galleria mellonella

News Publication Date: 10-Feb-2026

Web References:
10.1038/s41684-025-01665-7

Keywords: Animal research, Antibiotic resistance

Notum, an extracellular carboxylesterase, has recently garnered significant attention as a critical negative feedback regulator of the Wnt signaling pathway. Given Wnt signaling’s pivotal role in osteoblast differentiation and bone homeostasis, Notum emerges as an attractive target for therapeutic intervention in diseases characterized by impaired bone formation. In particular, glucocorticoid-induced osteoporosis, a common side effect of prolonged glucocorticoid therapy, negatively affects bone density and structural integrity, necessitating new treatment options.

At the heart of this study lies a smartly engineered near-infrared (NIR) fluorogenic substrate for Notum, designed specifically for rapid, high-throughput screening of natural products. This substrate enables the sensitive and efficient identification of Notum inhibitors from complex herbal extracts without the interference commonly encountered with conventional assays. The development of this NIR fluorogenic probe marks a significant advancement, facilitating a streamlined screening process with enhanced specificity and sensitivity.

Applying this cutting-edge assay, the research team systematically screened a diverse library of herbal medicines traditionally used for osteoporosis treatment. Among these, Bu-Gu-Zhi (BGZ), an ancient herbal formulation known for its bone-strengthening properties, stood out due to its potent inhibition of Notum enzymatic activity. Subsequent kinetic analyses revealed that BGZ acts in a competitive manner, restricting substrate binding within Notum’s catalytic pocket.

To further dissect the active constituents responsible for BGZ’s anti-Notum properties, the researchers adopted an integrative approach combining biochemical assays, phytochemical isolation, computational docking, and in vivo pharmacology. This multidisciplinary strategy ensured the precise identification and validation of key molecules while elucidating their mechanisms of action.

Three furanocoumarin derivatives prominently emerged as potent inhibitors within BGZ’s complex chemical matrix. Among them, 5-methoxypsoralen (5-MP) demonstrated the most robust inhibition coupled with an exceptional safety profile, making it a prime candidate for therapeutic development. Computational modeling provided molecular insights, revealing that 5-MP exerts its effect as a competitive inhibitor by lodging within the catalytic cavity of Notum, stabilized through hydrophobic interactions mainly with residues Trp128 and Phe268.

Corroborating these findings, cellular assays on MC3T3-E1 osteoblast precursors under dexamethasone-induced stress showed that 5-MP robustly restores osteoblast differentiation and Wnt pathway activation, effectively counteracting the glucocorticoid-mediated suppression. These cellular effects underscore the compound’s capability to reverse the impaired osteogenic signaling crucial for bone regeneration.

Moreover, the promise of 5-MP extends beyond cellular models into animal studies. In dexamethasone-induced osteoporotic mice, administration of 5-MP significantly increased bone mineral density (BMD) and enhanced both cancellous and cortical bone thickness. These morphological improvements were indicative of functional bone restoration, validating 5-MP’s potential as a disease-modifying agent rather than a symptomatic treatment.

This study not only advances our understanding of the molecular interplay between herbal constituents and enzymatic targets in bone pathology but also sets a new benchmark for drug discovery methodologies. By synergizing high-throughput biochemical screening with state-of-the-art computational and pharmacological evaluations, the research delineates a rapid and reliable pipeline that could be translated to other natural product-derived drug discovery efforts.

The implications for treating glucocorticoid-induced osteoporosis are significant. Current therapies largely focus on either inhibiting bone resorption or stimulating bone formation nonspecifically, often accompanied by adverse effects. Targeting Notum presents a specialization that directly modulates a key signaling axis essential for osteoblast function, promising better efficacy with fewer side effects.

In addition to its therapeutic value, 5-MP’s origin as a natural product provides favorable safety and tolerability parameters, often elusive in synthetic agents. Its known existence in traditional medicines potentially expedites regulatory paths and public acceptance, factors critical for translational success.

To summarize, this pioneering research sheds light on a potent natural compound, 5-methoxypsoralen, as a competitive and selective Notum inhibitor with multifaceted benefits in reversing glucocorticoid-induced bone loss. The combination of innovative assay development, integrative chemical biology, and robust translational validation marks a noteworthy leap forward in osteoporosis research.

With osteoporosis forming a growing global health concern, particularly among aging populations subjected to chronic glucocorticoid therapy, these findings resonate as a beacon of hope. The discovery not only reinforces the value of herbal medicines in modern pharmacology but also inspires new directions in therapeutic design leveraging endogenous signaling modulations.

Future research pursuing clinical evaluations of 5-MP and optimization of its pharmacodynamic and pharmacokinetic properties could pave the way for novel, safe, and effective treatments against glucocorticoid-induced osteoporosis, possibly expanding to other Wnt-associated bone disorders. This study exemplifies the marriage of traditional knowledge and cutting-edge science to address pressing medical needs.

Subject of Research: Discovery of anti-Notum natural compounds from herbal medicines for therapeutic use in glucocorticoid-induced osteoporosis.

Article Title: High-efficient discovering the potent anti-Notum agents from herbal medicines for combating glucocorticoid-induced osteoporosis.

News Publication Date: 2025

Web References:

• DOI: 10.1016/j.apsb.2025.06.004
• Journal: Acta Pharmaceutica Sinica B – ScienceDirect

Keywords: Notum, Near-infrared fluorogenic substrate, High-throughput screening, Glucocorticoid-induced osteoporosis (GIOP), 5-Methoxypsoralen, Wnt signaling, Osteoblast differentiation, Herbal medicines, Competitive inhibition, Bone mineral density.